MedPath

RITUAL Ultivision AI CADe Randomized Controlled Trial

Not Applicable
Terminated
Conditions
Colon Adenoma
Polyp of Colon
Adenoma Colon
Registration Number
NCT05732233
Lead Sponsor
Satisfai Health, Inc.
Brief Summary

Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas).

Ultivision AI CADe is indicated for white light colonoscopy only.

Detailed Description

Ultivision AI contains an image processing software and algorithm based on machine learning technology and convolutional neural networks (CNN).

The algorithm's primary function is to identify and highlight the likelihood of the presence of a colon polyp.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
137
Inclusion Criteria
  1. Age 45 to 75 years;
  2. Screening or surveillance colonoscopy.
  3. Iinformed consent
Exclusion Criteria
  1. Colorectal cancer;
  2. Inflammatory bowel disease, including Crohn's disease or ulcerative colitis;
  3. Polyposis syndrome including Familial Adenomatous Polyposis, Cowden syndome, Linch syndrome, Peutz-Jeghers syndrome, MUITYH associated polyposis, familial Colorectal Cancer type X;
  4. Positive Fecal Immunochemical Test;
  5. Use anti-platelet agents or anticoagulants that prevent polyps removal;
  6. Colon resection, not including the appendix;
  7. Subject is pregnant or lactating.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Adenoma Per Extraction (APE).During the procedure/surgery

Non inferiority of Ultivision-AI arm versus control arm. Where APE is the fraction of adenoma, sessile serrated lesions, and large (\>10mm) hyperplastic polyps of the proximal colon (caecum, ascending colon, hepatic flexure, and transverse colon) out of total number of resections.

Adenoma per Colonoscopy (APC)During the procedure/surgery

Superiority of Ultivision-AI arm versus control arm. APC is defined as the total number of histologically confirmed adenomas resected divided by the total number of colonoscopies.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

UC Irvine

🇺🇸

Irvine, California, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

University of Montreal Research Center (CRCHUM)

🇨🇦

Montréal (Québec), Montreal, Canada

Humanitas Research Hospital

🇮🇹

Milano, Italy

UC Irvine
🇺🇸Irvine, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.